Your browser doesn't support javascript.
loading
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Overman, Michael; Javle, Milind; Davis, Richard E; Vats, Pankaj; Kumar-Sinha, Chandan; Xiao, Lianchun; Mettu, Niharika B; Parra, Edwin R; Benson, Al B; Lopez, Charles D; Munugalavadla, Veerendra; Patel, Priti; Tao, Lin; Neelapu, Sattva; Maitra, Anirban.
Afiliación
  • Overman M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA moverman@mdanderson.org.
  • Javle M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Davis RE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Vats P; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Kumar-Sinha C; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Xiao L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mettu NB; Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA.
  • Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Benson AB; Department of Medicine, Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.
  • Lopez CD; Department of Oncology, School of Medicine, Oregon Health and Science University Foundation, Portland, Oregon, USA.
  • Munugalavadla V; Acerta Pharma LLC, Redwood City, California, USA.
  • Patel P; Acerta Pharma LLC, Redwood City, California, USA.
  • Tao L; Acerta Pharma LLC, Redwood City, California, USA.
  • Neelapu S; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Maitra A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 8(1)2020 02.
Article en En | MEDLINE | ID: mdl-32114502
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pirazinas / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Anticuerpos Monoclonales Humanizados / Agammaglobulinemia Tirosina Quinasa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pirazinas / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Anticuerpos Monoclonales Humanizados / Agammaglobulinemia Tirosina Quinasa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos